Treace Q3 Revenue Slips 4% but EBITDA Turns Positive, 2026 Loss Outlook Cut to $1M-$2M
TMCI has more than doubled off its 52-week low of $1.17.
Summary
Q3 revenue came in at $48.3M, down 4% from $50.2M a year ago, as mix shifted to lower-priced products and bunion kit volume fell, though the result slightly beat expectations. The bottom line improved sharply: net loss narrowed to $12.6M from $16.3M and Adjusted EBITDA flipped to positive $0.3M from $(2.6)M. Management cut the expected 2026 Adjusted EBITDA loss to $1.0M-$2.0M from $3.0M-$5.0M, and tightened the 2026 revenue range to $206M-$210M from $204M-$212M, implying a 1%-3% decline versus 2025. Cash burn fell 53% year to date, or $9.7M, leaving $39.8M of cash and securities against $60.0M of debt. The story is margin and cash discipline offsetting a shrinking top line; the revenue guide still points to contraction, so the positive EBITDA revision is the part that matters for the thesis.
At the time of this announcement, TMCI was trading at $4.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $271.8M. The 52-week trading range was $1.17 to $6.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.